Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Engage Grants Program

University of Western Ontario

$25,000.00

Mechanisms underlying the anti-Helicobacter pylori effects of Lactobacilli secretomes

EF 2017-18

Résumé
The bacterium Helicobacter pylori causes 65% of gastric ulcers and cancers worldwide. Antibiotic treatmentshave serious side effects and often fail because of bacterial resistance. Globally 30% of Canadians arecolonized and the aging of the population allows more gastric cancers to develop over decades. About 95% ofAboriginals are colonized and suffer from high rates of gastric ulcers and treatment failure. Lactobacilli arebacteria naturally present in the gut that are known as good bacteria with probiotic activity. Lactobacilliformulations developed by industry partner Lallemand Health Solutions improve anti- H. pylori treatments invivo and most of the 20 Lactobacilli tested in vitro in the Creuzenet lab released molecules with anti-H. pylorieffects. However, the mechanisms underlying those effects are not understood.We propose to examine how these molecules work, testing the hypothesis that they target specific sensorspresent in H. pylori. Understanding their mechanism of action will fill an important knowledge gap and willalso provide validation of active strains by bona fide scientific evidence, which is often lacking in the probioticfield. This will benefit our industrial partner who has a well-established tradition of backing all efficacy claimsby strong scientific data.Also, our work will help identify the best Lactobacilli to be used for specific purposes and facilitate theidentification of the beneficial anti-H. pylori molecules, which could be used in purified form to potentiate liveprobiotics in mixed formulations or to enhance the efficacy of current antibiotic treatments. These are directbenefits to the H. pylori-infected patients and the industrial partner who can explore a potentially significantmarket.Furthermore, understanding the molecular interactions that occur between H. pylori and Lactobacilli couldserve as a model system for other complex bacterial interactions. This could yield applications extending toother fields, such as nutrition, biotechnology or even bioremediation.
Programme
Engage Grants Program
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
514846-2017
Name nom
Creuzenet, Carole
Department département
Microbiology and Immunology
Organization id
36
Institution établissement
University of Western Ontario
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2017
Competition year année de concours
2017
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1553
Committee name en
Ontario Internal Decision Committee
Committee name fr
Comité de décision interne pour l'Ontario
Area of application code
1101
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Human health (including medically-related psychological research)
Area of application fr
Santé publique (y compris recherche psychologique liée à la médecine)
Research subject code
5201
Research subject group en
Microbiology
Research subject group fr
Microbiologie
Research subject en
Bacteriology
Research subject fr
Bactériologie
Partie
1
Nb partie
1
Application title
Mechanisms underlying the anti-Helicobacter pylori effects of Lactobacilli secretomes
Keyword
NSERC
Application summary
The bacterium Helicobacter pylori causes 65% of gastric ulcers and cancers worldwide. Antibiotic treatmentshave serious side effects and often fail because of bacterial resistance. Globally 30% of Canadians arecolonized and the aging of the population allows more gastric cancers to develop over decades. About 95% ofAboriginals are colonized and suffer from high rates of gastric ulcers and treatment failure. Lactobacilli arebacteria naturally present in the gut that are known as good bacteria with probiotic activity. Lactobacilliformulations developed by industry partner Lallemand Health Solutions improve anti- H. pylori treatments invivo and most of the 20 Lactobacilli tested in vitro in the Creuzenet lab released molecules with anti-H. pylorieffects. However, the mechanisms underlying those effects are not understood.We propose to examine how these molecules work, testing the hypothesis that they target specific sensorspresent in H. pylori. Understanding their mechanism of action will fill an important knowledge gap and willalso provide validation of active strains by bona fide scientific evidence, which is often lacking in the probioticfield. This will benefit our industrial partner who has a well-established tradition of backing all efficacy claimsby strong scientific data.Also, our work will help identify the best Lactobacilli to be used for specific purposes and facilitate theidentification of the beneficial anti-H. pylori molecules, which could be used in purified form to potentiate liveprobiotics in mixed formulations or to enhance the efficacy of current antibiotic treatments. These are directbenefits to the H. pylori-infected patients and the industrial partner who can explore a potentially significantmarket.Furthermore, understanding the molecular interactions that occur between H. pylori and Lactobacilli couldserve as a model system for other complex bacterial interactions. This could yield applications extending toother fields, such as nutrition, biotechnology or even bioremediation.